| [1] |
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2015,26(12):2375-2391.
doi: 10.1093/annonc/mdv383
pmid: 26371282
|
| [2] |
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559-574.
doi: 10.1093/annonc/mdv623
pmid: 26715621
|
| [3] |
Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. N Engl J Med, 2015,373(3):288-290.
doi: 10.1056/NEJMc1505197
URL
|
| [4] |
Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors[J]. Int J Cancer, 2019,145(3):639-648.
doi: 10.1002/ijc.32132
pmid: 30653255
|
| [5] |
Ma K, Lu Y, Jiang S, et al. The Relative Risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis[J]. Front Pharmacol, 2018,9:1430.
doi: 10.3389/fphar.2018.01430
URL
|
| [6] |
Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016,2(12):1607-1616.
doi: 10.1001/jamaoncol.2016.2453
pmid: 27540850
|
| [7] |
Jiang Y, Zhang N, Pang H, et al. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Ther Clin Risk Manag, 2019,15:293-302.
doi: 10.2147/TCRM.S191022
URL
|
| [8] |
Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systema-tic review and meta-analysis[J]. JAMA Oncol, 2018,4(12):1721-1728.
doi: 10.1001/jamaoncol.2018.3923
URL
|
| [9] |
Granier C, de Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer[J]. ESMO Open, 2017,2(2):e000213.
doi: 10.1136/esmoopen-2017-000213
URL
|
| [10] |
Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells?[J]. Clin Cancer Res, 2015,21(22):5047-5056.
doi: 10.1158/1078-0432.CCR-15-0685
pmid: 26567364
|
| [11] |
Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of Immune Checkpoint Blockade Therapy[J]. Cancer Discov, 2018,8(9):1069-1086.
doi: 10.1158/2159-8290.CD-18-0367
URL
|
| [12] |
Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells[J]. J Exp Med, 2009,206(13):3015-3029.
doi: 10.1084/jem.20090847
URL
|
| [13] |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012,12(4):252-264.
doi: 10.1038/nrc3239
pmid: 22437870
|
| [14] |
Soto F, Zhong L, Shannon VR, et al. Incidence and risk factors for pneumonitis associated with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer: A single center experience[J/OL]. J Clin Oncol, 2020,38(15_suppl):e15089-e15089.
|
| [15] |
Wu J, Hong D, Zhang X, et al. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis[J]. Sci Rep, 2017,7:44173.
doi: 10.1038/srep44173
URL
|
| [16] |
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717.
doi: 10.1200/JCO.2016.68.2005
URL
|
| [17] |
Huang Y, Fan H, Li N, et al. Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: systematic review and network meta-analysis[J]. Cancer Med, 2019,8(5):2664-2674.
doi: 10.1002/cam4.2104
URL
|
| [18] |
Chu X, Zhao J, Zhou J, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors[J]. Lung Cancer, 2020,150:76-82.
doi: 10.1016/j.lungcan.2020.08.015
URL
|
| [19] |
Hakozaki T, Richard C, Okuma Y, et al. Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy[J]. J Clin Oncol, 2020,38(15_suppl):3095-3095.
doi: 10.1200/JCO.19.02103
URL
|
| [20] |
Rogado J, Sánchez-Torres JM, Romero-Laorden N, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients[J]. Eur J Cancer, 2019,109:21-27.
doi: S0959-8049(18)31453-9
pmid: 30682533
|
| [21] |
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017,35(7):709-717.
doi: 10.1200/JCO.2016.68.2005
URL
|
| [22] |
Voong KR, Hazell SZ, Fu W, et al. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2019,20(4):e470-e479.
|
| [23] |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45(2):228-247.
doi: 10.1016/j.ejca.2008.10.026
pmid: 19097774
|
| [24] |
Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria[J]. Clin Cancer Res, 2009,15(23):7412-7420.
doi: 10.1158/1078-0432.CCR-09-1624
pmid: 19934295
|
| [25] |
Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res, 2016,22(24):6051-6060.
pmid: 27535979
|
| [26] |
Ferguson EC, Berkowitz EA. Lung CT: Part 2, The interstitial pneumonias--clinical, histologic, and CT manifestations[J]. Am J Roentgenol, 2012,199(4):W464-W476.
|
| [27] |
Gkiozos I, Kopitopoulou A, Kalkanis A, et al. Sarcoidosis-like reactions induced by checkpoint Inhibitors[J]. J Thorac Oncol, 2018,13(8):1076-1082.
doi: 10.1016/j.jtho.2018.04.031
URL
|
| [28] |
中华医学会呼吸学会分会肺癌学组. 免疫检查点抑制剂相关肺炎诊治专家共识[J]. 中华结核和呼吸杂志, 2019,42(11):820-825.
|
| [29] |
Pollack MH, Betof A, Dearden H, et al. Safety of resu-ming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma[J]. Ann Oncol, 2018,29(1):250-255.
doi: 10.1093/annonc/mdx642
pmid: 29045547
|
